Shares of Synthetic Biologics Inc (NYSEAMERICAN:SYN) rose 9.1% on Thursday . The company traded as high as $0.45 and last traded at $0.40. Approximately 589,529 shares changed hands during mid-day trading, a decline of 27% from the average daily volume of 809,710 shares. The stock had previously closed at $0.44.
A number of equities analysts have recently issued reports on the stock. BidaskClub cut shares of Synthetic Biologics from a “hold” rating to a “sell” rating in a research note on Saturday, November 4th. Zacks Investment Research cut shares of Synthetic Biologics from a “hold” rating to a “sell” rating in a research note on Thursday, January 11th.
The firm has a market capitalization of $56.58, a P/E ratio of -1.86 and a beta of 1.08.
ILLEGAL ACTIVITY WARNING: “Synthetic Biologics (SYN) Stock Price Up -9.1%” was published by Community Financial News and is the property of of Community Financial News. If you are reading this news story on another publication, it was illegally copied and republished in violation of United States & international copyright law. The legal version of this news story can be viewed at https://www.com-unik.info/2018/02/10/synthetic-biologics-syn-stock-price-up-9-1.html.
Synthetic Biologics Company Profile
Synthetic Biologics, Inc is a clinical-stage company. The Company is engaged in developing therapeutics to protect the gut microbiome while targeting pathogen-specific diseases. The Company’s lead product candidates in Phase II development are SYN-010, which is intended to reduce the impact of methane-producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation (IBS-C), and SYN-004, which is designed to protect the gut microbiome (gastrointestinal (GI) microflora) from the effects of certain commonly used intravenous (IV) antibiotics for the prevention of C.
Receive News & Ratings for Synthetic Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synthetic Biologics and related companies with MarketBeat.com's FREE daily email newsletter.